ArticleJournal of precision medicine (Amsterdam, Netherlands)2026
Accelerated Intrinsic Beating Rate in Heterogeneously Coupled Human Pluripotent Stem Cell-Derived Cardiomyocytes Can Underlie Focal Ventricular Tachycardia in Regenerative Therapy.
Article in Journal of precision medicine (Amsterdam, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In silico optimization of regenerative cell therapy in the infarcted human ventricles to mitigate arrhythmic burden.Stem cell reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cardiac regenerative therapies seek to replace damaged tissue following myocardial infarction to prevent heart failure. Human pluripotent stem-cell derived cardiomyocyte (hPSC-CM) injection can be used to remuscularize the heart and improve function but also cause ventricular tachycardia (VT). Electrical mapping studies suggest this VT is focal (i.e., driven by spontaneous excitations), but true mechanisms remain unknown. Computational approaches can provide new insights into these arrhythmias, but current simulation frameworks have not replicated focal VT. In this study, we conducted simulations with biophysically plausible representations of cell injection and the formation of gap junctions between hPSC-CM grafts and host tissue. We examined hPSC-CM ionic models with slow (1.1 Hz) and accelerated (2.5, 4 Hz) beating rates and assessed if these conditions could produce focal VT that is adequately rapid and robust to overpower sinus rhythm. For simulations conducted in human ventricular slice geometries with non-human primate graft patterns, we assessed susceptibility to focal VT. For the slow ionic model, focal VT was seen only at bradycardic heart rates (40 bpm); at faster heart rates (60 or 80 bpm), ectopic activity from the graft could not out-compete Purkinje-like endocardial excitations. In contrast, focal VT was seen for all tested heart rates when faster ionic models were used. Doubling graft size to cover larger infarct areas increased focal VT susceptibility in all cases. Thus, we conclude that post-injection increase in hPSC-CM spontaneous beating rate is a potential mechanism for focal VT, with applications in safer cell injection methods following experimental validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.